Arrowhead Pharmaceuticals, Inc. released its financial results for the 2025 fiscal year ending on September 30, 2025.
The company announced a significant FDA approval for REDEMPLO, marking a transformative milestone in their portfolio.
Arrowhead is positioned for future growth and new launches in discovery, clinical development, and commercial ventures.
FDA Approval of REDEMPLO
FDA approved REDEMPLO, the first siRNA medicine for adults with familial chylomicronemia syndrome.
One-REDEMPLO Pricing Model
Introduced a pricing model for consistent pricing across current and future indications.
Global Collaboration with Novartis
Entered a licensing agreement for ARO-SNCA with a $200 million upfront payment from Novartis.
ARO-DIMER-PA Clinical Trial
Initiated regulatory clearance for a Phase 1/2a trial for atherosclerotic cardiovascular disease treatment.
ARO-MAPT Clinical Trial
Sought regulatory clearance for a Phase 1/2a trial for tauopathies including Alzheimer's disease treatment.
- The FDA approval of REDEMPLO opens new opportunities for Arrowhead Pharmaceuticals in the rare disease space.
- Partnerships like the collaboration with Novartis demonstrate Arrowhead's potential for significant revenue from milestone payments and royalties.
- The initiation of clinical trials for innovative RNA interference therapies signals Arrowhead's commitment to advancing medical research and treatment options.
Arrowhead Pharmaceuticals' recent achievements and strategic moves position the company for continued growth and impact in the biopharmaceutical industry.